Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
Go back to Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments| AIMSI Technologies (NASDAQ: AIMT) | Delayed: 34.49 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.49 | 52 Week High | $27.31 | |||
| Open | $7.76 | 52 Week Low | $9.77 | |||
| Day High | $34.49 | P/E | N/A | |||
| Day Low | $34.49 | EPS | $0.00 | |||
| Volume | 42,896 | |||||
